Expression and prognostic value of cell-cycle-associated genes in lung squamous cell carcinoma

IF 3.2 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Gene Medicine Pub Date : 2024-08-22 DOI:10.1002/jgm.3735

Xinnan Xu, Kaiqi Jin, Xiaoxiong Xu, Yang Yang, Bin Zhou

{"title":"Expression and prognostic value of cell-cycle-associated genes in lung squamous cell carcinoma","authors":"Xinnan Xu, Kaiqi Jin, Xiaoxiong Xu, Yang Yang, Bin Zhou","doi":"10.1002/jgm.3735","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Lung cancer continues to be a prevalent cause of cancer-related deaths worldwide, with lung squamous carcinoma (LUSC) being a significant subtype characterized by comparatively low survival rates. Extensive molecular studies on LUSC have been conducted; however, the clinical importance of cell-cycle-associated genes has rarely been examined. This study aimed to investigate the relationship between these genes and LUSC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The expression trends of genes related to the cell cycle in a group of patients with LUSC were analyzed. Clinical information and mRNA expression data were obtained from The Cancer Genome Atlas via cBioportal. Multiple analyses have been performed to investigate the association between these genes and LUSC.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Three clusters were identified based on the mRNA expression of 124 cell cycle-associated genes. Cluster 3 exhibited the worst prognosis. A comparative analysis showed that nine expressed genes differed distinctly among all the clusters. Among these nine genes, elevated expression of <i>CDK4</i> was strongly associated with positive prognosis. Furthermore, the expression of <i>ANAPC11</i>, <i>ANAPC5</i>, and <i>ORC4</i> correlated with the advancement of LUSC pathological stages.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Gene expression profiles associated with the cell cycle across various LUSC subtypes were identified, highlighting that specific genes are related to prognosis and disease stages. Based on these results, new prognostic strategies, patient stratification, and targeted therapy trials have been conducted for LUSC.</p>\n </section>\n </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gene Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgm.3735","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Lung cancer continues to be a prevalent cause of cancer-related deaths worldwide, with lung squamous carcinoma (LUSC) being a significant subtype characterized by comparatively low survival rates. Extensive molecular studies on LUSC have been conducted; however, the clinical importance of cell-cycle-associated genes has rarely been examined. This study aimed to investigate the relationship between these genes and LUSC.

Methods

The expression trends of genes related to the cell cycle in a group of patients with LUSC were analyzed. Clinical information and mRNA expression data were obtained from The Cancer Genome Atlas via cBioportal. Multiple analyses have been performed to investigate the association between these genes and LUSC.

Results

Three clusters were identified based on the mRNA expression of 124 cell cycle-associated genes. Cluster 3 exhibited the worst prognosis. A comparative analysis showed that nine expressed genes differed distinctly among all the clusters. Among these nine genes, elevated expression of CDK4 was strongly associated with positive prognosis. Furthermore, the expression of ANAPC11, ANAPC5, and ORC4 correlated with the advancement of LUSC pathological stages.

Conclusions

Gene expression profiles associated with the cell cycle across various LUSC subtypes were identified, highlighting that specific genes are related to prognosis and disease stages. Based on these results, new prognostic strategies, patient stratification, and targeted therapy trials have been conducted for LUSC.

Abstract Image

查看原文本刊更多论文

肺鳞状细胞癌细胞周期相关基因的表达和预后价值。

背景：肺癌仍然是全球癌症相关死亡的一个普遍原因，其中肺鳞状癌（LUSC）是一个重要的亚型，其特点是生存率相对较低。目前已对肺鳞癌进行了广泛的分子研究，但细胞周期相关基因的临床重要性却很少得到研究。本研究旨在探讨这些基因与 LUSC 之间的关系：方法：分析一组 LUSC 患者中细胞周期相关基因的表达趋势。临床信息和mRNA表达数据通过cBioportal从癌症基因组图谱中获取。为了研究这些基因与 LUSC 之间的关联，研究人员进行了多重分析：结果：根据 124 个细胞周期相关基因的 mRNA 表达，确定了三个群组。第 3 组的预后最差。对比分析表明，有九个表达基因在所有群组中存在明显差异。在这九个基因中，CDK4的表达升高与预后呈阳性密切相关。此外，ANAPC11、ANAPC5和ORC4的表达与LUSC病理分期的进展相关：结论：研究发现了不同LUSC亚型中与细胞周期相关的基因表达谱，突显出特定基因与预后和疾病分期相关。基于这些结果，我们已针对 LUSC 开展了新的预后策略、患者分层和靶向治疗试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gene Medicine 医学-生物工程与应用微生物

CiteScore

6.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The aims and scope of The Journal of Gene Medicine include cutting-edge science of gene transfer and its applications in gene and cell therapy, genome editing with precision nucleases, epigenetic modifications of host genome by small molecules, siRNA, microRNA and other noncoding RNAs as therapeutic gene-modulating agents or targets, biomarkers for precision medicine, and gene-based prognostic/diagnostic studies. Key areas of interest are the design of novel synthetic and viral vectors, novel therapeutic nucleic acids such as mRNA, modified microRNAs and siRNAs, antagomirs, aptamers, antisense and exon-skipping agents, refined genome editing tools using nucleic acid /protein combinations, physically or biologically targeted delivery and gene modulation, ex vivo or in vivo pharmacological studies including animal models, and human clinical trials. Papers presenting research into the mechanisms underlying transfer and action of gene medicines, the application of the new technologies for stem cell modification or nucleic acid based vaccines, the identification of new genetic or epigenetic variations as biomarkers to direct precision medicine, and the preclinical/clinical development of gene/expression signatures indicative of diagnosis or predictive of prognosis are also encouraged.